Governance Beam Therapeutics Inc.

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
31.22 ^USD	-2.59%		+13.32%	+12.63%

01-11	Beam Therapeutics sets strategic priorities for its genetic disease & hematology franchises	RE
01-07	UBS Initiates Beam Therapeutics at Neutral With $28 Price Target	MT

Executive Committee: Beam Therapeutics Inc.

Manager

Positions heldSince

John Evans

48 year

Comptroller/Controller/Auditor	08/08/2024
Chief Executive Officer	31/12/2016

Amy Simon

62 year

Chief Tech/Sci/R&D Officer

14/03/2021

Sravan Emany

48 year

Director of Finance/CFO

18/12/2024

Holly Manning

Investor Relations Contact

Gopi Shanker

Chief Tech/Sci/R&D Officer

20/03/2023

Manmohan Singh

61 year

Chief Tech/Sci/R&D Officer

31/07/2022

Susan O'Connor

63 year

Human Resources Officer

31/07/2017

Christine Bellon

61 year

General Counsel

31/03/2019

Giuseppe Ciaramella

57 year

President

23/01/2020

Bethany Cavanagh

Comptroller/Controller/Auditor	-
Treasurer	-

Composition of the Board of Directors: Beam Therapeutics Inc.

Director

CommitteesSince

John Maraganore

62 year

Governance Committee Chair
Nominating Committee Chair
Compensation Committee	29/02/2024
Audit Committee	29/02/2024

Christi Shaw

59 year

Audit Committee	13/12/2023
Governance Committee	13/12/2023
Nominating Committee	13/12/2023

Graham Cooper

56 year

Compensation Committee	11/05/2022
Audit Committee Chair	09/10/2019

Mark Fishman

75 year

Governance Committee
Nominating Committee

Kathleen Walsh

70 year

Audit Committee	09/01/2021
Compensation Committee	09/01/2021

Carole Ho

53 year

Compensation Committee

14/11/2018

Chirfi Guindo

60 year

Compensation Committee

01/12/2024

John Evans

48 year

Director/Board Member

31/12/2016

Latest Appointments: Beam Therapeutics Inc.

06/12/24	Beam Therapeutics Appoints Sravan Emany as CFO	MT
06/12/24	Beam Therapeutics Inc. Appoints Sravan K. Emany as Chief Financial Officer, Effective December 19, 2024	CI
04/12/24	Beam Therapeutics Inc. Announces the Appointment of Chirfi Guindo to Its Board of Directors	CI
15/07/24	Beam Therapeutics' Finance Chief Terry-Ann Burrell Leaving in August	MT
15/07/24	Beam Therapeutics CFO Terry-Ann Burrell Departing in August	MT
15/07/24	Beam Therapeutics Inc. Announces Resignation of Terry-Ann Burrell as Chief Financial Officer, Effective August 9, 2024	CI
14/12/23	Beam Therapeutics Inc. Appoints Christi Shaw to Its Board of Directors	CI

More news

Former Officers and Directors: Beam Therapeutics Inc.

Insider

Positions held

SinceUntil

Terry-Ann Burrell

Director of Finance/CFO	31/07/2019	08/08/2024
Treasurer	31/08/2019	08/08/2024

Kristina Burow

Director/Board Member	31/05/2017	04/06/2024
Independent Dir/Board Member	31/05/2017	04/06/2024

Courtney Wallace

Private Equity Investor	30/04/2018	30/09/2020
Corporate Officer/Principal	30/09/2020	31/07/2023

Francine Gregoire

Corporate Officer/Principal

31/03/2018

30/11/2022

Christine Swenson

General Counsel

15/03/2020

31/12/2021

Robert Nelsen

Director/Board Member	31/05/2017	20/05/2021
Independent Dir/Board Member	31/05/2017	20/05/2021

Stephen Knight

Director/Board Member	-	21/04/2021
Independent Dir/Board Member	-	21/04/2021

Brian Busser

Corporate Officer/Principal

31/01/2019

30/09/2020

Dana Levasseur

Corporate Officer/Principal

30/06/2018

31/03/2020

Feng Zhang

Director/Board Member	24/01/2017	20/02/2019
Founder	24/01/2017	20/02/2019

Suzanne Fleming

Comptroller/Controller/Auditor	-	-
Treasurer	31/01/2019	-

David R. Liu

Founder

24/01/2017

J. Joung

Founder

24/01/2017

Nicole Gaudelli

Founder

24/01/2017

Alexis Komor

Founder

24/01/2017

Age distribution of managers

Parity Men Women

Male	13
Female	5

Of which Executive Committee

Male	7
Female	3

Of which Directors

Male	6
Female	2

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Employees

510

Sector

Biotechnology & Medical Research

Calendar

03-02 - Q4 2025 Earnings Release (Projected)

More about the company